Driving the Best Science to Meet Global Health Challenge s

 
asymptomatic infections
A . Sakuntabhai, A . Rouvinski, W . Dejnirattisai, E . Simon-
Loriere, J . Mongkolsapaya, G . Screaton, F . Rey (Paris, FR; 
London, GB) 
INV.3.2.6.005 
Dengue control in the IDAMS consortium
18 .00
 
T . Jaenisch (Heidelberg, DE) 
INV.3.2.6.006 
The global distribution of the arbovirus vectors Aedes 
18 .15
 
aegypti and Ae. albopictus
M .U .G . Kraemer, N . Golding, O .J . Brady, J .P . Messina, 
D .L . Smith, G .R .W . Wint, S .I . Hay (Oxford, GB) 

87
SCIENTIFIC PROGRAMME 
Tuesday, 8 September 2015
Scientific Pr
og
ramme
17 .00 – 18 .30
 
Parallel Session 3.2.3. 
Samarkand
 
(Disease systems) 
 Leishmaniasis 
 
Convener and Chair: Johannes Blum (Basel, CH) 
O.3.2.3.001 
Effectiveness, safety profile of new treatments and long 
17 .00
 
term outcome for Kala-azar at public health facilities in 
Bihar, India
V . Goyal, R . Mahajan, B . Sharma, N . Strub-Wourgaft, 
M . Balasegaram, S . Rijal, S . Ellis, F . Alves, S . Burza, T . Sunyoto, 
N . Lima, K . Pandey, V .N .R . Das, R .K . Topno, P . Das, J . Alvar 
(New Delhi, Patna, IN; Geneva, CH; Barcelona, ES) 
O.3.2.3.002 
IgG1 as a potential biomarker of post-chemotherapeutic 
17 .15
 
relapse in visceral leishmaniasis, and adaptation to a rapid 
diagnostic test
T . Bhattacharyya, K . Hayes, H . Hafezi, P . Mertens, 
C . Thunissen, S . Sundar, S . El-Safi, S . Rijal, M . Boelaert, 
M .A . Miles (London, GB; Antwerp, Gembloux, BE; Varanasi, 
IN; Khartoum, SD; Dharan, NP) 
O.3.2.3.003 
Portable HECT-CL thermotherapy for L. tropica cutaneous 
17 .30
 
leishmaniasis in Aleppo, Syria during 2014
R . Witzig, A . Ismail, A . Sayer, F . Hanoush, E . Ismail (New 
Orleans, US; Aleppo, SY) 
O.3.2.3.004 
Post kala-azar dermal leishmaniasis treated with liposomal
17 .45
 
amphotericin B (AmBisome)
S . Burza, M . den Boer, R . Mahajan, A .K . Das, G . Mitra, 
P . Almeida, M .A . Lima, A . Be-Nazir, T . Sunyoto, P . Das, 
K . Ritmeijer (Delhi, Patna, IN; Antwerp, BE; Amsterdam, NL; 
Dhaka, BD; Barcelona, ES) 
O.3.2.3.005 
Mimotope-based vaccines of Leishmania infantum antigens
18 .00
 
and their protective efficacy against visceral leishmaniasis
L .E . Costa, L .R . Goulart, N .C . Pereira, M .I . Lima, M .C . Duarte, 
V .T . Martins, P .S . Lage, D . Menezes-Souza, T .G . Ribeiro, 
M .N . Melo, A .P . Fernandes, M . Soto, C .A . Tavares, M .A . Chávez-
Fumagalli, E .A . Coelho (Belo Horizonte, Uberlândia, BR; 
Davis, US; Madrid, ES) 
O.3.2.3.006 
Innovative approaches to visceral leishmaniasis: 18F-FDG
18 .15
 
PET/CT as a diagnostic tool and treatment with a single 
dose of liposomal amphotericin B
E . Vanino, J .J . Morigi, L . Attard, S . Ianniruberto, V . Ambrosini, 
S . Varani, P . Viale (Bologna, IT) 

88
SCIENTIFIC PROGRAMME  Wednesday, 9 September 2015
09 .00 – 09 .30
 
Plenary Session 8 
San Francisco 
 
Disease systems 
 
Chair: Antoine Flahault (Geneva, CH) 
INV.PL8.001 
NCD policy in South Africa: progress and challenges using 
fiscal, legislative and regulatory levers 
K .J . Hofman (Johannesburg, ZA) 
09 .30 – 10 .00
 
Plenary Session 9 
San Francisco 
 
Health and social systems 
 
Chair: Shally Awasthi (Lucknow, IN) 
INV.PL9.001 
Achieving effective community participation for health 
under resource constraints
H .A . Mwenesi (Washington, US) 
10 .30 – 12 .00
 
Parallel Session 5.6.1. 
Sydney
 
(From research to implementation) 
 
Challenges of surveillance-response in the disease 
elimination phase 
 
Convener and Chair: Xiao-Nong Zhou (Shanghai, CN) 
INV.5.6.1.001 
Feasibility and roadmap analysis on malaria elimination 
10 .30
 
in China
W . Yang, X . Zhou (Beijing, CN) 
O.5.6.1.002 
Enhanced dengue sentinel surveillance in Sri Lanka
11 .00
 
 H . Tissera, S . Gunasena, D . da Silva, O . Sessions, 
P . Palihawadana, A . Amarasinghe, C . Muthukuda, C . Botheju, 
W .-Y . Leong, W . Lohr, P . Byass, A . Wilder-Smith, D . Gubler 
(Colombo, LK; Singapore, SG; Umea, SE) 
O.5.6.1.003 
Fine scale participatory mapping of malaria infection 
11 .15
 
clusters by using routinely collected health facility data in 
urban Dar es Salaam, Tanzania
Y .P . Mlacha, P .P . Chaki, A .D . Malishee, V .M . Mwakalinga, 
N .J . Govella, A .J . Limwagu, J .M . Paliga, D .F . Msellemu, 
Z .D . Mageni, D .J . Terlouw, G .F . Killeen, S . Dongus (Dar es 
Salaam, TZ; Johannesburg, ZA; Liverpool, GB; Blantyre, MW; 
Basel, CH) 
O.5.6.1.004 
Evaluation of the national case-based measles surveillance
11 .30
 
system in South Africa: January 2009 to December 2013
E .D . Mathatha, M . Hlanzi, J .M . Manamela, M . Suchaed 
(Johannesburg, Pretoria, ZA) 
O.5.6.1.005 
Characterizing types of human mobility to inform 
11 .45
 
differential and targeted malaria elimination strategies in 
Northeast Cambodia
K . Peeters Grietens, C . Gryseels, S . Dierickx, M . Bannister-Tyrrell, 
S . Trienekens, S . Uk, P . Phoeuk, S . Suon, S . Set, R . Gerrets, 
S . Hoibak, J . Muela Ribera, S . Hausmann-Muela, S . Tho, 
L . Durnez, V . Sluydts, U . d’Alessandro, M . Coosemans, A . Erhart 
(Antwerp, Tessenderlo, BE; Nagasaki, JP; Phnom Penh, KH; 
Amsterdam, NL; Geneva, CH; London, GB; Fajara, GM) 

89
SCIENTIFIC PROGRAMME  Wednesday, 9 September 2015
Scientific Pr
og
ramme
10 .30 – 12 .00
 
Parallel Session 5.6.3. 
Singapore
 
(From research to implementation) 
 
Surveillance of substandard and falsified medicines 
 
Convener and Chair: Paul Newton (Vientiane, LA) 
INV.5.6.3.001 
WHO surveillance and monitoring of substandard and 
10 .30
 
falsified medical products
Michael Deats (Geneva, CH) 
O.5.6.3.002 
The quality of paediatric medicines supplied by private 
11 .00
 
wholesalers in Kinshasa, DRC
R . Ravinetto, D . Ngeleka Mutolo, B . de Spiegeleere, R . Marini, 
E . Hasker, B . Schiavetti (Antwerp, Ghent, Liège, BE;  
Kinshasa, CD) 
O.5.6.3.003 
DIFAEM-EPN Minilab-network
11 .15
 
A . Petersen (Tübingen, DE) 
O.5.6.3.004 
Quality assessment of the pharmaceutical products 
11 .30
 
management system in Chad
D . Mbaibarem, Y . Djimtaingar, G . Doumde, O . Aoun, 
F .M . Lahaye, C . Rapp (Alexandria, EG; Djamena, TD; Saint-
Mande Cedex, FR) 
O.5.6.3.005 
Systematic sampling approach reveals fewer falsified first 
11 .45
 
line antimalarials than previously reported
H . Kaur, M .D . Green, F .M . Fernández (London, GB; Atlanta, US) 

90
SCIENTIFIC PROGRAMME  Wednesday, 9 September 2015
10 .30 – 12 .00
 
Parallel Session 5.4.2. 
Montreal
 
(From research to implementation) 
 
Large cohorts and big data and disease/
 
risk mapping-predicting 
 
Convener and Chair: Vincent E. Mooser (Lausanne, CH)  
 
Convener and Chair: Nicole Probst-Hensch (Basel, CH) 
INV.5.4.2.001 
Tracking outbreaks of emerging infectious diseases using 
10 .30
 
Big Data
Antoine Flahault (Geneva, CH) 
O.5.4.2.002 
Modification of ambient air pollution and diabetes associ-
11 .00
 
tion by type 2 diabetes genetic risk score of 48 variants
I .C . Eze, M . Imboden, A . Kumar, A . von Eckardstein, 
D . Stolz, M .W . Gerbase, N . Künzli, T . Rochat, F . Kronenberg, 
C . Schindler, N . Probst-Hensch (Basel, Geneva, Zurich, CH; 
Oxford, GB; Innsbruck, AT) 
O.5.4.2.003 
Malaria mortality in a hypoendemic area of North-Eastern 
11 .15
 
South Africa: population-based surveillance from 1992 to 
2013 reveals an increasing malaria burden
P . Byass, M .A . Collinson, S .M . Tollman, K . Kahn (Umea, SE; 
Johannesburg, ZA) 
O.5.4.2.004 
High participation and engagement rate in a systematic 
11 .30
 
hospital-based genomic medicine research project with 
broad consent
M . Bochud, C . Currat, L . Chapatte, C . Roth, V .E . Mooser 
(Lausanne, CH) 
O.5.4.2.005 
MIDATA cooperatives – citizen-controlled use of health 
11 .45
 
data is a pre-requiste for big data analysis, economic 
success and a democratization of the personal data 
economy
E . Hafen (Zurich, CH) 

91
SCIENTIFIC PROGRAMME  Wednesday, 9 September 2015
Scientific Pr
og
ramme
10 .30 – 12 .00
 
Parallel Session 3.1.12. 
Delhi
 
(Disease systems) 
 
The struggle with MDR-TB 
 
Convener and Chair: Klaus Reither (Basel, CH) 
INV.3.1.12.001 
Host - directed therapies in TB - wishful thinking or clinical
10 .30
 reality
Markus Maeurer (Stockholm, SE) 
O.3.1.12.002 
Towards first in human clinical trial with the novel drug 
11 .00
 
candidate PBTZ169
J .-Y . Gillon, B . Lechartier, V .A . Makarov, S .T . Cole (Lausanne, 
CH; Moscow, RU) 
O.3.1.12.003 
Novel molecular approaches to assessing the burden of 
11 .15
 
drug-resistant tuberculosis
A .S . Dean, M . Zignol, K . Floyd (Geneva, CH) 
O.3.1.12.004 
Pyrazinamide resistance in Mycobacterium tuberculosis
11 .30
 
develops after resistance to rifampicin and is increasingly 
common as strains become resistant to additional antibiotics
A .K . Alame Emane, P . Xu, C . Pierre-Audigier, V . Cadet-Daniel, 
X . Shen, M . Sraouia, J .F . Djoba Siawaya, H . Takiff, Q . Gao, 
B . Gicquel (Paris, FR; Libreville, GA; Shanghai, CN; Caracas, VU) 
O.3.1.12.005 
Impact of the M. tuberculosis genetic background on the
11 .45
 
acquisition of drug resistance-conferring mutations
S . Borrell, J . Feldmann, R . Castro, A . Trauner, S . Gagneux 
(Basel, CH) 
10 .30 – 12 .00
 
Society Session 9 
Boston 1 
 
Forum for Global Health Research (FGHR, Norway): 
task shifting dilemmas in light of the human resource 
shortage in health 
 
Convener and Chair: Johanne Sundby (Oslo, NO) 
SS9.001 
Task shifting from TBA to surgery, some challenges
10 .30
 
Johanne Sundby (Oslo, NO) 
SS9.002 
Traditional birth attendants- do they make a difference?
10 .40
 
Margit Steinholt (Tromsø, NO) 
SS9.003 
Task shifting in abortion provision
11 .00
 
Bela Ganatra (Geneva, CH) 
SS9.004 
Surgical task shifting – quick fix or safe solution?
11 .20
 
Karine Nordstrand (Oslo, NO) 
SS9.005 
Increasing surgical capacity in Sierra Leone by training
11 .40
 
Medical Doctors and Community Health Officers in 
surgical and obstetric life-saving surgery
Alex J . van Duinen (Trondheim, NO) 

92
SCIENTIFIC PROGRAMME  Wednesday, 9 September 2015
10 .30 – 12 .00
 
Parallel Session 3.2.15. 
Boston 2
 
(Disease systems) 
 
Helminth infections – diagnosis 
 
Convener and Chair: Jennifer Keiser (Basel, CH) 
O.3.2.15.001 
Is PCR the next gold standard for the diagnosis of 
10 .30
 
Schistosoma in stool? A comparison with microscopy in 
Senegal and Kenya
L . Meurs, E . Brienen, M . Mbow, E .A . Ochola, S . Mboup, 
D .M .S . Karanja, W .E . Secor, K . Polman, L . van Lieshout 
(Antwerp, BE; Leiden, NL; Dakar, SN; Kisumu, KE; Atlanta, US) 
O.3.2.15.002 
Sensitivity of Strongyloides IgG antibody detection by 
10 .45
 
ELISA among immunocompromised patients
L . Gétaz, P . Zamora, R . Castro, M . Kramer, S . Lisarazu, 
F . Chappuis (Geneva, CH; Cochabamba, Santa Cruz, BO) 
O.3.2.15.003 
Innovative diagnostic tools to control cystic echinococcosis
11 .00
 
 M .P . Maurelli, L . Rinaldi, P . Pepe, D . Ianniello, A . Amadesi, 
G . Cringoli (Naples, IT) 
O.3.2.15.004 
An ultra-sensitive urine-based assay targeting the circulat-
11 .15
 
ing anodic antigen (CAA) for diagnosis of urogenital and 
intestinal schistosomiasis in low-endemic areas
G .J . van Dam, C .J . de Dood, D . Kornelis, L . van Lieshout, 
P .L .A .M . Corstjens (Leiden, NL) 
O.3.2.15.005 
Comparison of different diagnostic procedures, including 
11 .30
 
mini-FLOTAC and multiplex real-time PCR, for the diagnosis 
of soil transmitted helminths and protozoa in stool 
samples from Ende, Indonesia
L . van Lieshout, E .A .T . Brienen, M .M .M . Kaisar, Y . Djuardi, 
E . Sartono, T . Supali (Leiden, NL; Jakarta, ID) 
O.3.2.15.006 
Nanobody
®
-based sandwich enzyme-linked immunosorr-
11 .45
 
bent assay for the detection of Toxocara canis excretory- 
secretory proteins
F .J . Morales, I . Sariego Ramos, K . Polman, S . Muyldermans 
(Antwerp, Brussels, BE; La Habana, CU) 

93
SCIENTIFIC PROGRAMME  Wednesday, 9 September 2015
Scientific Pr
og
ramme
10 .30 – 12 .00
 
Parallel Session 4.3.1. 
Shanghai 1
 
(Health and social systems) 
 
Effective development cooperation in a complex 
 environment 
 
Convener and Chair: Karel Gyselinck (Brussels, BE) 
INV.4.3.1.001 
“Keep it simple, stupid”:  The aid/health sector conundrum
10 .30
 
Rosalind Eyben (Brighton, GB) 
INV.4.3.1.002 
Sustainable development results through complexity 
11 .00
 
management and learning
Paul Bossyns (Brussels, BE) 
O.4.3.1.003 
Are Global Health Initiatives contributing to health system
11 .30
 
strengthening in Zanzibar? 
I . Litwin-Davies, B .C . Forsberg (Stockholm, SE) 
O.4.3.1.004 
Political pressure from donors to reduce or end health aid 
11 .45
 
on basis of country income classification risks damage 
to people‘s health in middle income countries and 
undermining effectiveness of global health initiatives
A . Markham, K . Akerfeldt, M . Philips (Brussels, BE; London, GB) 

94
SCIENTIFIC PROGRAMME  Wednesday, 9 September 2015
10 .30 – 12 .00
 
Parallel Session 3.2.16. 
Shanghai 2
 
(Disease systems) 
 
R&D for African and South-American Trypanosomiasis
 
Convener and Chair: Pascal Maeser (Basel, CH) 
O.3.2.16.001 
A new diagnostic algorithm for Trypanosoma brucei 
10 .30
 
gambiense human African trypanosomiasis (HAT) case 
detection in a low prevalence setting in North Western 
Uganda
C . Wamboga, E . Matovu, S . Bieler, P . Bessel, J . Ndungu 
(Kampala, UG; Geneva, CH; Edinburgh, GB) 
O.3.2.16.002 
Development of a rapid diagnostic test for active case 
10 .45
 
detection in sleeping sickness control: recHAT Sero-Strip
Q . Gilleman, P . Büscher, P . Mertens, T . Leclipteux (Antwerp, 
Gembloux, BE) 
O.3.2.16.003 
Migration between Côte d‘Ivoire and bordering countries 
11 .00
 
and Human African Trypanosomiasis
M . Koffi, F . Courtin, L . Kouakou, B . Sepe, V . Jamonneau, 
B . Bonfoh, E . Schelling (Abidjan, Côte d‘Ivoire, Daloa, CI; 
Bobo-Dioulasso, BF; Basel, CH) 
O.3.2.16.004 
Research and development landscape in Chagas disease
11 .15
 
I . Ribeiro (Geneva, CH) 
O.3.2.16.005 
High frequency of Trypanosoma cruzi polyclonal infections
11 .30
 
detected by molecular characterization of natural parasite 
populations in Chagas disease patients enrolled in clinical 
trials with antiparasitic drugs
J .C . Ramirez, G .R . Acevedo, R . Parrado, S . Villarroel, A . de 
la Barra, L . Garcia, J . Gascon, L . Ortiz, F . Torrico, F .P . Alves, 
I . Ribeiro, A .G . Schijman (Buenos Aires, AR; Cochabamba, 
Tarija, BO; Barcelona, ES; Geneva, CH) 
O.3.2.16.006 
Immunogenicity and efficacy of a subunit therapeutic 
11 .45
 
vaccine against Chagas disease
K .M . Jones, J .L . Respress, M .A . Barry, B .P . Keegan, 
C .M . Beaumier, J . Pollet, B . Zhan, A .L . Kendricks, N . Yoshida, 
L . Feng, M .E . Bottazzi, P .J . Hotez (Houston, Research Triangle 
Park, US) 

95
SCIENTIFIC PROGRAMME  Wednesday, 9 September 2015
Scientific Pr
og
ramme
10 .30 – 12 .00
 
Parallel Session 3.1.8. 
Kairo 1
 
(Disease systems) 
 
Insecticide resistance 
 Convener and Chair: Pie Müller (Basel, CH) 
INV.3.1.8.001 
The implications of pyrethroid resistance for malaria 
10 .30
 
control and elimination
Hilary Ranson (Liverpool, GB) 
O.3.1.8.002 
Malaria vector control at a crossroads: public health 
11 .00
 
entomology and the drive to elimination
A .P . Mnzava, M .B . Macdonald, T .B . Knox, E .A . Temu, C .J . Shiff 
(Basel, Geneva, CH; Baltimore, US) 
O.3.1.8.003 
Anopheles arabiensis is not successfully controlled by 
11 .15
 
indoor residual spraying in Northwest Tanzania: 
implication for malaria vector control in the area
J . Kitau, N . Protopopoff, A . Wright, P . West, F .W . Mosha, 
W . Kisinza, I . Kleinschmidt, M . Rowland (Moshi, Tanga, TZ; 
London, GB) 
O.3.1.8.004 
Insecticide susceptibility of Anopheles gambiae s.l. in 
11 .30
 
sentinel sites in the Democratic Republic of Congo
F . Wat‘senga, E . Manzambi, G . Ilombe, R . Mulumbu, S . Fasine, 
G . Binene, J . Losimba, S . Irish, E . Dotson (Kinshasa, CD; 
Atlanta, US) 
O.3.1.8.005 
Micro-encapsulated pirimiphos-methyl shows high insecti-
11 .45
 
cidal efficacy against pyrethroid-resistant malaria vectors
E . Tchicaya, C . Nsanzabana, T .A . Smith, J . Donzé, M .L . de 
Hipsl, P . Müller, Y . Tano, O .J .T . Briët, J . Utzinger, B .G . Koudou 
(Abidjan, CI; Liverpool, Oxford, GB; Basel, Neuchâtel, CH) 

96
SCIENTIFIC PROGRAMME  Wednesday, 9 September 2015
10 .30 – 12 .00
 
Society Session 10 
Kairo 2 
 
Network Medicus Mundi Switzerland (MMS): 
 
Swiss Health NGO‘s for implementation research 
 
Chair: Martin Leschhorn Strebel (Basel, CH) 
SS10.001 
Welcome address
10 .30
 
Martin Leschhorn Strebel (Basel, CH) 
SS10.002 
The role of NGOs in implementation research
10 .35
 
John Reeder (Geneva, CH) 
SS10.003 
The way forward for NGO driven implementation research
10 .55
 
in Switzerland
Jochen Ehmer (Lucerne, CH) 
SS10.004 
Implementation research in Switzerland – a vision
11 .10
 
Nicole Moran (Konstanz, DE) 
SS10.005 
Panel Debate
11 .20
 
 John Reeder (Geneva, CH)  
Ingrid Mason (Berne, CH)  
Thomas Schwarz (Basel, CH)  
Susanna Hausmann (Berne, CH)  
Kaspar Wyss (Basel, CH) 
SS10.006 
Summary and next steps
11 .55
 
Thomas Gass (Berne, CH) 

97
SCIENTIFIC PROGRAMME  Wednesday, 9 September 2015
Scientific Pr
og
ramme
10 .30 – 12 .00
 
Parallel Session 3.2.8. 
Samarkand
 
(Disease systems) 
 Leprosy 
elimination 
 
Convener and Chair: Bart Vander Plaetse (Basel, CH)  
 
Convener and Chair: Peter Steinmann (Basel, CH) 
INV.3.2.8.001 
Leprosy elimination, lessons from experience
10 .30
 
William Cairns Smith (Aberdeen, GB) 
INV.3.2.8.002 
Leprosy post-exposure prophylaxis (LPEP) project
10 .55
 
Bart Vander Plaetse (Basel, CH) 
O.3.2.8.003 
Global elimination of leprosy by 2020: are we on track?
11 .10
 
D .J . Blok, S .J . de Vlas, J .H . Richardus (Rotterdam, NL) 
O.3.2.8.004 
Cambodia retrospective contact tracing project: innovation
11 .25